Lysine PCA

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H597514

CAS#: 30657-38-6

Description: Lysine PCA is a bioactive chemical.

Chemical Structure

img
Lysine PCA
CAS# 30657-38-6
Instruction

Theoretical Analysis

Hodoodo Cat#: H597514
Name: Lysine PCA
CAS#: 30657-38-6
Chemical Formula: C11H21N3O5
Exact Mass: 275.15
Molecular Weight: 275.300
Elemental Analysis: C, 47.99; H, 7.69; N, 15.26; O, 29.06

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 98-79-3 (PCA)   56-87-1 (lysine)   30657-38-6    

Synonym: Lysine PCA;

IUPAC/Chemical Name: (S)-5-oxopyrrolidine-2-carboxylic acid compound with L-lysine (1:1)

InChi Key: GSTSUZHIVMCRLR-RVZXSAGBSA-N

InChi Code: InChI=1S/C6H14N2O2.C5H7NO3/c7-4-2-1-3-5(8)6(9)10;7-4-2-1-3(6-4)5(8)9/h5H,1-4,7-8H2,(H,9,10);3H,1-2H2,(H,6,7)(H,8,9)/t5-;3-/m00/s1

SMILES Code: N[C@@H](CCCCN)C(O)=O.O=C(O)[C@H](CC1)NC1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 275.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pidhatika B, Chen Y, Coullerez G, Al-Bataineh S, Textor M. ToF-SIMS analysis of poly(L-lysine)-graft-poly(2-methyl-2-oxazoline) ultrathin adlayers. Anal Bioanal Chem. 2014 Feb;406(5):1509-17. doi: 10.1007/s00216-013-7537-2. Epub 2013 Dec 14. PubMed PMID: 24337163.

2: Pathak R, Philizaire M, Mujtaba S. Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells. Cancers (Basel). 2015 Aug 19;7(3):1622-42. doi: 10.3390/cancers7030854. Review. PubMed PMID: 26295410; PubMed Central PMCID: PMC4586787.

3: Li X, Li T, Chen D, Zhang P, Song Y, Zhu H, Xiao Y, Xing Y. Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway. Oncol Rep. 2016 Jan;35(1):584-92. doi: 10.3892/or.2015.4362. Epub 2015 Oct 30. PubMed PMID: 26534764.

4: Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, Helgason CD. The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer. 2012 Aug 6;11:52. doi: 10.1186/1476-4598-11-52. Review. PubMed PMID: 22867098; PubMed Central PMCID: PMC3441810.

5: Silva DA, Domínguez-Ramírez L, Rojo-Domínguez A, Sosa-Peinado A. Conformational dynamics of L-lysine, L-arginine, L-ornithine binding protein reveals ligand-dependent plasticity. Proteins. 2011 Jul;79(7):2097-108. doi: 10.1002/prot.23030. Epub 2011 May 2. PubMed PMID: 21538545.

6: Ho SM, Cheong A, Lam HM, Hu WY, Shi GB, Zhu X, Chen J, Zhang X, Medvedovic M, Leung YK, Prins GS. Exposure of Human Prostaspheres to Bisphenol A Epigenetically Regulates SNORD Family Noncoding RNAs via Histone Modification. Endocrinology. 2015 Nov;156(11):3984-95. doi: 10.1210/en.2015-1067. Epub 2015 Aug 6. PubMed PMID: 26248216; PubMed Central PMCID: PMC4606748.

7: Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, de Jong M, van Weerden WM. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. J Nucl Med. 2015 Jul;56(7):1094-9. doi: 10.2967/jnumed.115.156729. Epub 2015 May 14. PubMed PMID: 25977460.

8: Pang W, Huang S, Tung CC, Huang MH. Patient-controlled analgesia with tramadol versus tramadol plus lysine acetyl salicylate. Anesth Analg. 2000 Nov;91(5):1226-9. PubMed PMID: 11049913.

9: Gang X, Yang Y, Zhong J, Jiang K, Pan Y, Karnes RJ, Zhang J, Xu W, Wang G, Huang H. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. Oncotarget. 2016 Mar 22;7(12):15135-49. doi: 10.18632/oncotarget.7715. PubMed PMID: 26934656; PubMed Central PMCID: PMC4924775.

10: García-Tobilla P, Solórzano SR, Salido-Guadarrama I, González-Covarrubias V, Morales-Montor G, Díaz-Otañez CE, Rodríguez-Dorantes M. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms. Gene. 2016 Nov 30;593(2):292-301. doi: 10.1016/j.gene.2016.08.030. Epub 2016 Aug 26. PubMed PMID: 27570179.

11: Pang W, Mok MS, Ku MC, Huang MH. Patient-controlled analgesia with morphine plus lysine acetyl salicylate. Anesth Analg. 1999 Oct;89(4):995-8. PubMed PMID: 10512278.

12: Zhu S, Xu Y, Song M, Chen G, Wang H, Zhao Y, Wang Z, Li F. PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening. Mol Med Rep. 2016 Oct;14(4):3357-61. doi: 10.3892/mmr.2016.5605. Epub 2016 Aug 8. PubMed PMID: 27511603.

13: Wagner MS, Pasche S, Castner DG, Textor M. Characterization of poly(L-lysine)-graft-poly(ethylene glycol) assembled monolayers on niobium pentoxide substrates using time-of-flight secondary ion mass spectrometry and multivariate analysis. Anal Chem. 2004 Mar 1;76(5):1483-92. PubMed PMID: 14987107.

14: Lindberg J, Mills IG, Klevebring D, Liu W, Neiman M, Xu J, Wikström P, Wiklund P, Wiklund F, Egevad L, Grönberg H. The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol. 2013 Apr;63(4):702-8. doi: 10.1016/j.eururo.2012.11.053. Epub 2012 Dec 5. PubMed PMID: 23265383.

15: Chaiswing L, Zhong W, Oberley TD. Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression. Free Radic Biol Med. 2014 Feb;67:342-52. doi: 10.1016/j.freeradbiomed.2013.11.006. Epub 2013 Nov 22. PubMed PMID: 24269899; PubMed Central PMCID: PMC3945156.

16: Vieira FQ, Costa-Pinheiro P, Almeida-Rios D, Graça I, Monteiro-Reis S, Simões-Sousa S, Carneiro I, Sousa EJ, Godinho MI, Baltazar F, Henrique R, Jerónimo C. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3. Oncotarget. 2015 May 30;6(15):13644-57. PubMed PMID: 25980436; PubMed Central PMCID: PMC4537039.

17: White-Al Habeeb NM, Garcia J, Fleshner N, Bapat B. Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells. Prostate. 2016 Dec;76(16):1507-1518. doi: 10.1002/pros.23235. Epub 2016 Jul 12. PubMed PMID: 27404348.

18: Ngollo M, Lebert A, Dagdemir A, Judes G, Karsli-Ceppioglu S, Daures M, Kemeny JL, Penault-Llorca F, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters. BMC Cancer. 2014 Dec 23;14:994. doi: 10.1186/1471-2407-14-994. PubMed PMID: 25535400; PubMed Central PMCID: PMC4364597.

19: Behbahani TE, Kahl P, von der Gathen J, Heukamp LC, Baumann C, Gütgemann I, Walter B, Hofstädter F, Bastian PJ, von Ruecker A, Müller SC, Rogenhofer S, Ellinger J. Alterations of global histone H4K20 methylation during prostate carcinogenesis. BMC Urol. 2012 Mar 13;12:5. doi: 10.1186/1471-2490-12-5. PubMed PMID: 22413846; PubMed Central PMCID: PMC3323457.

20: Vieira FQ, Costa-Pinheiro P, Ramalho-Carvalho J, Pereira A, Menezes FD, Antunes L, Carneiro I, Oliveira J, Henrique R, Jerónimo C. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr Relat Cancer. 2013 Dec 16;21(1):51-61. doi: 10.1530/ERC-13-0375. Print 2014 Feb. PubMed PMID: 24200674.